Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramer’s radar. Cramer noted that the company could not perform as ...

Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech ...

AstraZeneca’s AZN third-quarter 2025 core earnings of $1.19 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.14 per share. Core earnings of $2.38 per share rose 14% year ...

Jon Smith explains why investors can look across the pond for stocks with attractive dividend forecasts and shares a specific ...

Stock futures were little changed Thursday, a day after major indexes rebounded from a selloff in tech stocks caused by ...

MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment ...

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are ...

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a ...

Russia's Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the ...